Claudia Jiménez
Corporate Officer/Principal chez Cellerix SA
Profil
Claudia Jiménez is currently the Director of Business Development at Cellerix SA. Prior to this, she worked as a Principal at Portigon AG and as a General Manager at Algenex SL.
She holds a Master's degree in Business Administration from Instituto de Empresa SL, an undergraduate degree from Hochschule Reutlingen, and another undergraduate degree from Instituto Catolico de Administracion y Direccion de Empresas.
Postes actifs de Claudia Jiménez
| Sociétés | Poste | Début |
|---|---|---|
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Corporate Officer/Principal | 25/11/2009 |
Anciens postes connus de Claudia Jiménez
| Sociétés | Poste | Fin |
|---|---|---|
Algenex SL
 Algenex SL BiotechnologyHealth Technology Algenex SL develops and manufactures recombinant proteins. It specializes in the baculovirus vector-based innovative technologies to manufacture recombinant proteins used to produce vaccines, diagnostic reagents and therapeutic molecules. The company was founded by Jose Angel Martinez Escribano and Covadonga Alonso on January 19, 2005 and is headquartered in Pozuelo de Alarcon, Spain. | Directeur Général | - |
Portigon AG
 Portigon AG Regional BanksFinance Portigon AG engages in the management of its own assets. It also provides financial services and conducts banking activities. The company was founded in 1969 and is headquartered in Duesseldorf, Germany. | Corporate Officer/Principal | - |
Formation de Claudia Jiménez
| Instituto Catolico de Administracion y Direccion de Empresas | Undergraduate Degree |
| Hochschule Reutlingen | Undergraduate Degree |
| Instituto de Empresa SL | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Health Technology |
Portigon AG
Portigon AG Regional BanksFinance Portigon AG engages in the management of its own assets. It also provides financial services and conducts banking activities. The company was founded in 1969 and is headquartered in Duesseldorf, Germany. | Finance |
Algenex SL
Algenex SL BiotechnologyHealth Technology Algenex SL develops and manufactures recombinant proteins. It specializes in the baculovirus vector-based innovative technologies to manufacture recombinant proteins used to produce vaccines, diagnostic reagents and therapeutic molecules. The company was founded by Jose Angel Martinez Escribano and Covadonga Alonso on January 19, 2005 and is headquartered in Pozuelo de Alarcon, Spain. | Health Technology |
